Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Anal Cancer Metastatic × Gemcitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 611 Carcinoma, Non-Small-Cell Lung 282 Breast Neoplasms 149 Neoplasms 146 Lung Neoplasms 139 Urinary Bladder Neoplasms 136 Neoplasm Metastasis 122 Cholangiocarcinoma 96 Ovarian Neoplasms 87 Biliary Tract Neoplasms 79 Nasopharyngeal Carcinoma 66 Lymphoma, Large B-Cell, Diffuse 66 Lymphoma 61 Recurrence 55 Sarcoma 54 Gallbladder Neoplasms 53 Hodgkin Disease 48 Carcinoma, Transitional Cell 47 Triple Negative Breast Neoplasms 45 Colorectal Neoplasms 43 Lymphoma, Non-Hodgkin 41 Fallopian Tube Neoplasms 41 Adenocarcinoma 41 Bile Duct Neoplasms 36 Non-Muscle Invasive Bladder Neoplasms 28 Uterine Cervical Neoplasms 27 Unspecified Adult Solid Tumor, Protocol Specific 27 Carcinoma, Ovarian Epithelial 27 Carcinoma 27 Adenocarcinoma of Lung 24

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡